IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506620-87-00

Acronym

IMPORTANT TRIAL

Enrollment

495

Registered

2023-11-27

Start date

2024-01-25

Completion date

Unknown

Last updated

2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Breast Cancer in older patients

Brief summary

Time to treatment failure

Detailed description

Overall Treatment Utility, Overall survival, Progression free survival, Time to chemotherapy initiation, Toxicity, QoL, Time to QoL deterioration, Cost-effectiveness

Interventions

DRUGVerzenios 50 mg film-coated tablets

DRUGArimidex® 1 mg film-coated tablets

DRUGVerzenios 100 mg film-coated tablets

DRUGIBRANCE 100 mg hard capsules

DRUGAromasin 25 mg coated tablets

DRUGFaslodex 250 mg solution for injection.

DRUGIBRANCE 125 mg hard capsules

DRUGKisqali 200 mg film-coated tablets

DRUGFemara 2

DRUG5 mg plėvele dengtos tabletės

DRUGIBRANCE 75 mg hard capsules

DRUGVerzenios 150 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to treatment failure	—

Secondary

Measure	Time frame
Overall Treatment Utility, Overall survival, Progression free survival, Time to chemotherapy initiation, Toxicity, QoL, Time to QoL deterioration, Cost-effectiveness	—

Countries

Finland, Greece, Italy, Norway, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026